NASDAQ:RXST RxSight (RXST) Stock Forecast, Price & News $26.75 -1.14 (-4.09%) (As of 10/2/2023 ET) Add Compare Share Share Today's Range$26.62▼$27.9050-Day Range$26.75▼$33.3752-Week Range$9.78▼$33.77Volume264,382 shsAverage Volume425,006 shsMarket Capitalization$953.37 millionP/E RatioN/ADividend YieldN/APrice Target$30.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media RxSight MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside14.0% Upside$30.50 Price TargetShort InterestHealthy3.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingSelling Shares$1.84 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.66) to ($1.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector364th out of 975 stocksOphthalmic Goods Industry6th out of 7 stocks 2.4 Analyst's Opinion Consensus RatingRxSight has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.50, RxSight has a forecasted upside of 14.0% from its current price of $26.75.Amount of Analyst CoverageRxSight has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.79% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RxSight has recently decreased by 24.82%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRxSight does not currently pay a dividend.Dividend GrowthRxSight does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RXST. Previous Next 2.8 News and Social Media Coverage News SentimentRxSight has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for RxSight this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for RXST on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added RxSight to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RxSight insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,839,683.00 in company stock.Percentage Held by Insiders21.13% of the stock of RxSight is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.51% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for RxSight are expected to grow in the coming year, from ($1.66) to ($1.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RxSight is -13.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RxSight is -13.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRxSight has a P/B Ratio of 8.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About RxSight (NASDAQ:RXST) StockRxSight, Inc., an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.Read More RXST Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RXST Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comHead-To-Head Survey: RxSight (NASDAQ:RXST) and Signature Eyewear (OTCMKTS:SEYE)September 7, 2023 | finance.yahoo.comRxSight, Inc. (RXST) Crossed Above the 20-Day Moving Average: What That Means for InvestorsOctober 3, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 24, 2023 | finance.yahoo.comRxSight, Inc. (RXST) Interactive Stock Chart - Yahoo FinanceAugust 18, 2023 | fool.comRxSight (NASDAQ: RXST)August 16, 2023 | msn.comRxSight: Poised To Make Waves In Ophthalmic MarketAugust 14, 2023 | finance.yahoo.comWith 40% ownership, RxSight, Inc. (NASDAQ:RXST) has piqued the interest of institutional investorsAugust 12, 2023 | markets.businessinsider.comJ.P. Morgan Sticks to Their Buy Rating for RxSight (RXST)October 3, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 8, 2023 | msn.comOppenheimer Maintains RxSight (RXST) Outperform RecommendationAugust 8, 2023 | msn.comNeedham Reiterates RxSight (RXST) Buy RecommendationAugust 8, 2023 | markets.businessinsider.comWhere RxSight Stands With AnalystsAugust 8, 2023 | finance.yahoo.comRxSight, Inc. (NASDAQ:RXST) Q2 2023 Earnings Call TranscriptAugust 4, 2023 | benzinga.comRxSight's Earnings: A PreviewAugust 3, 2023 | msn.comRxSight (RXST) Price Target Increased by 11.03% to 30.80July 27, 2023 | finance.yahoo.comRxSight, Inc. to Report Second Quarter Financial Results on August 7, 2023July 12, 2023 | markets.businessinsider.comRxSight Is A Potential Acquisition Target: Analyst Highlights How LAL Revenue Mix Could Drive Share Price To $45+July 12, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for RxSightJuly 6, 2023 | msn.comRxSight (RXST) Price Target Increased by 16.24% to 27.74June 18, 2023 | finance.yahoo.comInvestors in RxSight (NASDAQ:RXST) have seen respectable returns of 79% over the past yearJune 6, 2023 | msn.comBTIG Maintains RxSight (RXST) Buy RecommendationMay 16, 2023 | seekingalpha.comRxSight: Improved Margin OutlookMay 12, 2023 | msn.comWells Fargo Maintains RxSight (RXST) Equal-Weight RecommendationMay 9, 2023 | markets.businessinsider.comBTIG Keeps Their Buy Rating on RxSight (RXST)May 9, 2023 | finance.yahoo.comRxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue EstimatesMay 9, 2023 | finance.yahoo.comRxSight, Inc. Reports First Quarter 2023 Financial ResultsMay 2, 2023 | finance.yahoo.comWill RxSight, Inc. (RXST) Report Negative Earnings Next Week? What You Should KnowSee More Headlines Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Email Address RXST Company Calendar Last Earnings8/07/2023Today10/02/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Ophthalmic goods Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RXST CUSIPN/A CIK1111485 Webwww.rxsight.com Phone949-521-7830FaxN/AEmployees292Year FoundedN/APrice Target and Rating Average Stock Price Forecast$30.50 High Stock Price Forecast$36.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+14.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-66,760,000.00 Net Margins-88.72% Pretax Margin-88.67% Return on Equity-48.72% Return on Assets-33.79% Debt Debt-to-Equity Ratio0.12 Current Ratio10.89 Quick Ratio9.81 Sales & Book Value Annual Sales$49.01 million Price / Sales19.45 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book8.26Miscellaneous Outstanding Shares35,640,000Free Float28,112,000Market Cap$953.37 million OptionableNot Optionable Beta0.73 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Ronald M. Kurtz M.D. (Age 60)Pres, CEO & Director Comp: $1.03MMs. Shelley B. Thunen (Age 69)CFO & Assistant Sec. Comp: $651.36kDr. Ilya Goldshleger Ph.D. (Age 48)Chief Operating Officer Comp: $657.81kMr. Eric J. Weinberg (Age 62)Chief Commercial Officer Comp: $638.9kMs. Rebecca WillistonVP of Accounting & Fin.Mr. Matt Haller Ph.D.Chief Technology OfficerAlex HuangInvestor RelationsMr. Roy FreemanVP of MarketingMs. Caroline VaughnVP of HRMr. Scott GainesSr. VP of Commercial Operations & Bus. ProcessMore ExecutivesKey CompetitorsNational VisionNASDAQ:EYEWarby ParkerNYSE:WRBYSTAAR SurgicalNASDAQ:STAAPhreesiaNYSE:PHRDeciphera PharmaceuticalsNASDAQ:DCPHView All CompetitorsInsiders & InstitutionsBakker Juliet TammenomsSold 2,950 sharesTotal: $88,529.50 ($30.01/share)Bakker Juliet TammenomsSold 19,967 sharesTotal: $601,006.70 ($30.10/share)Shweta ManiarSold 4,292 sharesTotal: $120,433.52 ($28.06/share)Bakker Juliet TammenomsSold 16,208 sharesTotal: $474,084.00 ($29.25/share)California State Teachers Retirement SystemBought 18,112 shares on 8/21/2023Ownership: 0.076%View All Insider TransactionsView All Institutional Transactions RXST Stock - Frequently Asked Questions Should I buy or sell RxSight stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RxSight in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RXST shares. View RXST analyst ratings or view top-rated stocks. What is RxSight's stock price forecast for 2023? 5 analysts have issued 12-month price objectives for RxSight's stock. Their RXST share price forecasts range from $20.00 to $36.00. On average, they expect the company's stock price to reach $30.50 in the next year. This suggests a possible upside of 14.0% from the stock's current price. View analysts price targets for RXST or view top-rated stocks among Wall Street analysts. How have RXST shares performed in 2023? RxSight's stock was trading at $12.67 at the beginning of the year. Since then, RXST stock has increased by 111.1% and is now trading at $26.75. View the best growth stocks for 2023 here. Are investors shorting RxSight? RxSight saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 1,060,000 shares, a decrease of 24.8% from the August 31st total of 1,410,000 shares. Based on an average daily trading volume, of 462,600 shares, the short-interest ratio is presently 2.3 days. Approximately 3.8% of the shares of the stock are sold short. View RxSight's Short Interest. When is RxSight's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our RXST earnings forecast. How were RxSight's earnings last quarter? RxSight, Inc. (NASDAQ:RXST) announced its quarterly earnings data on Monday, August, 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.47) by $0.07. The firm had revenue of $20.81 million for the quarter, compared to analyst estimates of $19.21 million. RxSight had a negative net margin of 88.72% and a negative trailing twelve-month return on equity of 48.72%. What ETF holds RxSight's stock ? Invesco Dorsey Wright Healthcare Momentum ETF holds 53,792 shares of RXST stock, representing 1.07% of its portfolio. What guidance has RxSight issued on next quarter's earnings? RxSight updated its FY 2023 earnings guidance on Monday, August, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $81.00 million-$86.00 million, compared to the consensus revenue estimate of $81.88 million. When did RxSight IPO? (RXST) raised $125 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,350,000 shares at $16.00-$18.00 per share. What is RxSight's stock symbol? RxSight trades on the NASDAQ under the ticker symbol "RXST." How do I buy shares of RxSight? Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is RxSight's stock price today? One share of RXST stock can currently be purchased for approximately $26.75. How much money does RxSight make? RxSight (NASDAQ:RXST) has a market capitalization of $953.37 million and generates $49.01 million in revenue each year. The company earns $-66,760,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. How many employees does RxSight have? The company employs 292 workers across the globe. How can I contact RxSight? The official website for the company is www.rxsight.com. The company can be reached via phone at 949-521-7830 or via email at ir@rxsight.com. This page (NASDAQ:RXST) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.